NCT03334214 - Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

November 28, 2018

Study Completion Date

November 28, 2018

Conditions

Hepatic Steatosis

Interventions

DRUG

IONIS DGAT2Rx

Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks

DRUG

Placebo

Saline 0.9%

Trial Locations (22)

1036

Ionis Investigational Site, Budapest

1083

Ionis Investigational Site, Budapest

1088

Ionis Investigational Site, Budapest

3000

Ionis Investigational Site, Hatvan

3529

Ionis Investigational Site, Miskolc

8000

Ionis Investigational Site, Székesfehérvár

B3H 2Y9

Ionis Investigational Site, Halifax

G7H 7K9

Ionis Investigational Site, Chicoutimi

85-863

Ionis Investigational Site, Bydgoszcz

41-902

Ionis Investigational Site, Bytom

22-100

Ionis Investigational Site, Chełm

40-752

Ionis Investigational Site, Katowice

31-501

Ionis Investigational Site, Krakow

31-530

Ionis Investigational Site, Krakow

93-509

Ionis Investigational Site, Lodz

41-400

Ionis Investigational Site, Mysłowice

33-122

Ionis Investigational Site, Wierzchosławice

50-127

Ionis Investigational Site, Wroclaw

50-220

Ionis Investigational Site, Wroclaw

50-349

Ionis Investigational Site, Wroclaw

DD1 9SY

Ionis Investigational Site, Dundee

NG7 2UH

Ionis Investigational Site, Nottingham